In 2009
Release time: 2010-06-30 & nbsp & nbsp & nbsp Source:
A few days ago，The Institute of Southern Medical Economics officially released the latest ranking of the top 100 Chinese pharmaceutical industry in 2009。Guangzhou Pharmaceutical Group Co., Ltd., including 6 Guangdong pharmaceutical companies on the list。
It is reported，The statistical indicator caliber selected by the "Top 100 China Pharmaceutical Industry in 2009" is the sales revenue of the enterprise's annual pharmaceutical stake online sports bettingindustry (according to the statistics of China Accounting Standards); The object of participating in the selection is registered in China (excluding Hong Kong, Macao and Taiwan)、Pharmaceutical companies that are mainly engaged in the pharmaceutical manufacturing industry，That is in the enterprise industrial and commercial registration，Drug manufacturing business placed in the company with the highest business business scope of the company。
The overall scale of the finalists increases
According to the introduction of the organizer，Ranking is screening in more than 4,700 pharmaceutical companies across the country，The final line of the enterprise scale is 891 million yuan。The overall size of the pharmaceutical industry enterprise that was shortlisted for the top 100 list has also been improved。There are 6 companies with a size of more than 8 billion yuan，Enterprises with a scale of more than 2 billion yuan have exceeded half，53。According to statistical data, it shows，2009，The total sales revenue of the top 100 companies reached 339.266 billion yuan，increased by 25.10%year -on -year; at the same time，The sales revenue of the top ten companies accounts for 42.27%of the total shortlisted stake betting appenterprises in the finals，The average growth rate of its sales revenue of its enterprise is 24.1%。
40 companies rose again
Affected by the rules of this ranking，Many shortlisted companies have also changed a lot，There are only 10 companies that are the same as the previous position。Where，38 companies have declined; 40 companies have risen again，The secondary improvement of Shenzhen East Sunshine Industry is the most obvious，From the 83th place in the previous session, 34 -bit。
Hualan Biological Engineering Co., Ltd. benefited from the concept of innovation and development.，The first appearance on the top 100 list，and the remaining 11 new finalists also use innovation as the only rule for enterprises to develop rapidly，With both chemical preparations and Chinese medicine production, they have entered the top 100。
Guangyao Group "small steps" forward
According to the information Times reporter, the reporter understands，As the leader of Guangdong pharmaceutical companies，Guangyao Group's rise has risen from 7th last year to 6，But there is still a certain gap with the second place in 2005。
According to the research and analysis of the Institute of Medical Economics of Southern Medical Economics，Stake Sports BettingIn the competitive pharmaceutical market，The speed of innovation development speed determines the life and death of potential competitors。OTC drugs, most of the old brands of Guangyao Group，Relatively fixed growth, so there is not much growth。
Huang Dingyi, a researcher at the pharmaceutical industry of First Financial Research Institute, pointed out，There are 45 national medicine protection varieties in Guangyao，Exclusive varieties of traditional Chinese medicine in 20 countries，Enterprise brands are very good，The variety is also good，But many subsidiaries do not closely linked together，No joint force formed。On the other hand，Compared with other wholly state -owned companies，less supported by the government。
An industry insider revealed to reporters: As the new medical reform policy advances，The top three companies have significantly accelerated the pace of development in 2009，M & A and acquisition and integration of many enterprises that complement the company's product structure，Innovation becomes the main engine of development and transformation。"But，Compared to the positive of these companies，The development of Guangyao Group is relatively slow。"The person said。
It is reported，The statistical indicator caliber selected by the "Top 100 China Pharmaceutical Industry in 2009" is the sales revenue of the enterprise's annual pharmaceutical stake online sports bettingindustry (according to the statistics of China Accounting Standards); The object of participating in the selection is registered in China (excluding Hong Kong, Macao and Taiwan)、Pharmaceutical companies that are mainly engaged in the pharmaceutical manufacturing industry，That is in the enterprise industrial and commercial registration，Drug manufacturing business placed in the company with the highest business business scope of the company。
The overall scale of the finalists increases
According to the introduction of the organizer，Ranking is screening in more than 4,700 pharmaceutical companies across the country，The final line of the enterprise scale is 891 million yuan。The overall size of the pharmaceutical industry enterprise that was shortlisted for the top 100 list has also been improved。There are 6 companies with a size of more than 8 billion yuan，Enterprises with a scale of more than 2 billion yuan have exceeded half，53。According to statistical data, it shows，2009，The total sales revenue of the top 100 companies reached 339.266 billion yuan，increased by 25.10%year -on -year; at the same time，The sales revenue of the top ten companies accounts for 42.27%of the total shortlisted stake betting appenterprises in the finals，The average growth rate of its sales revenue of its enterprise is 24.1%。
40 companies rose again
Affected by the rules of this ranking，Many shortlisted companies have also changed a lot，There are only 10 companies that are the same as the previous position。Where，38 companies have declined; 40 companies have risen again，The secondary improvement of Shenzhen East Sunshine Industry is the most obvious，From the 83th place in the previous session, 34 -bit。
Hualan Biological Engineering Co., Ltd. benefited from the concept of innovation and development.，The first appearance on the top 100 list，and the remaining 11 new finalists also use innovation as the only rule for enterprises to develop rapidly，With both chemical preparations and Chinese medicine production, they have entered the top 100。
Guangyao Group "small steps" forward
According to the information Times reporter, the reporter understands，As the leader of Guangdong pharmaceutical companies，Guangyao Group's rise has risen from 7th last year to 6，But there is still a certain gap with the second place in 2005。
According to the research and analysis of the Institute of Medical Economics of Southern Medical Economics，Stake Sports BettingIn the competitive pharmaceutical market，The speed of innovation development speed determines the life and death of potential competitors。OTC drugs, most of the old brands of Guangyao Group，Relatively fixed growth, so there is not much growth。
Huang Dingyi, a researcher at the pharmaceutical industry of First Financial Research Institute, pointed out，There are 45 national medicine protection varieties in Guangyao，Exclusive varieties of traditional Chinese medicine in 20 countries，Enterprise brands are very good，The variety is also good，But many subsidiaries do not closely linked together，No joint force formed。On the other hand，Compared with other wholly state -owned companies，less supported by the government。
An industry insider revealed to reporters: As the new medical reform policy advances，The top three companies have significantly accelerated the pace of development in 2009，M & A and acquisition and integration of many enterprises that complement the company's product structure，Innovation becomes the main engine of development and transformation。"But，Compared to the positive of these companies，The development of Guangyao Group is relatively slow。"The person said。
